Bcp-All
Checking Date & Time
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
Finding Sources
Reading File
Reading File
Searching PubMed
"B-cell precursor ALL" OR "BCP-ALL" treatment
Reading File
Searching PubMed
"acute lymphoblastic leukemia"[MeSH Terms] AND "precursor B-Cell Lymphoblastic Leukemia-Lymphoma"[MeSH Terms]
I now have comprehensive information from multiple textbooks. Here is a complete overview of BCP-ALL (B-Cell Precursor Acute Lymphoblastic Leukemia):
BCP-ALL — B-Cell Precursor Acute Lymphoblastic Leukemia
Definition & Overview
BCP-ALL (also called B-ALL or pre-B ALL) is a neoplasm of immature B-cell precursors (lymphoblasts) arising primarily in the bone marrow. It constitutes ~85% of all ALL cases and is the most common cancer of children, with ~2,500 new cases/year in the US.
- Peak age: ~3 years (corresponding to peak normal bone marrow pre-B cell numbers)
- Sex: Slightly more frequent in boys
- Ethnicity: Highest incidence in Hispanic/Latino children
- Also occurs in adults, but with worse prognosis
— Robbins, Cotran & Kumar Pathologic Basis of Disease, p. 556
Immunophenotype
Blasts express the following markers:
| Marker | BCP-ALL | Burkitt | Precursor T-ALL |
|---|---|---|---|
| TdT (nuclear) | + | − | + |
| HLA-DR | + | + | − |
| CD19 | + | + | − |
| CD10 (CALLA) | +/− | + | − |
| CD20 | −/+ | + | − |
| sIg | − | + | − |
| CD34 | + | − | variable |
| CD99 | + | + | |
| PAX5 | + | − |
Key subtypes by maturity:
- Pro-B ALL (~10%): CD19+/CD22+ only, CD10−
- Common ALL / CALLA+ ALL (~50–60%): CD19+/CD22+, CD10+ — best prognosis among B-ALL subtypes
- Pre-B ALL (~10%): above + intracytoplasmic immunoglobulin
- Mature B-ALL (<5%): surface immunoglobulin present
— Goldman-Cecil Medicine, p. 1921; Quick Compendium of Clinical Pathology, p. 256
Pathogenesis & Genetics
~90% of ALLs have chromosomal abnormalities. Key driver mutations disrupt transcription factors essential for early B-cell development:
| Gene/Abnormality | Translocation | Frequency | Prognosis |
|---|---|---|---|
| ETV6::RUNX1 (TEL::AML1) | t(12;21) | 25% of children | Good |
| Hyperdiploidy (>50 chr) | — | 25% of children | Good |
| BCR::ABL1 (Philadelphia+) | t(9;22) | 25% of adults, 3% of children | Poor |
| KMT2A (MLL) rearrangement | t(4;11), others | Infants | Poor |
| Hypodiploidy (<46 chr) | — | <5% | Poor |
| BCR-ABL1–like ALL | No t(9;22), similar expression | Variable | Poor |
| IGH::IL3 | t(5;14) | Rare | Background eosinophilia |
Other mutations include PAX5, TCF3, RUNX1, BCR::ABL1, KMT2A, PBX1. Complementary driver mutations affecting tyrosine kinase activity and RAS signaling are also common; deep sequencing suggests <10 total mutations produce full-blown ALL.
— Robbins, p. 557; Quick Compendium, p. 256
Clinical Presentation
Symptoms result from bone marrow replacement and pancytopenia:
- Fatigue, pallor (anemia)
- Fever, infections (neutropenia)
- Bleeding/petechiae (thrombocytopenia)
- Bone pain, lymphadenopathy, hepatosplenomegaly
- CNS involvement (headache, cranial nerve palsies)
Treatment
Treatment is divided into three phases:
1. Induction (3–4 weeks)
- Vincristine + prednisone + L-asparaginase ± daunorubicin
- CR achieved in >95% of children, ~80–90% of adults
- For CD20+ Ph− ALL: add rituximab (improves outcomes)
2. Post-Remission (Consolidation + Maintenance)
- Consolidation: high-dose methotrexate, cyclophosphamide, cytarabine (6–8 intensive courses)
- Maintenance: daily 6-mercaptopurine + weekly methotrexate for 2–3 years
- Addition of blinatumomab (anti-CD19 × anti-CD3 bispecific antibody) during consolidation → molecular remission rates ↑, >90% survival at 18 months
3. CNS Prophylaxis
- Intrathecal methotrexate ± cytarabine (4 cycles, alternating)
Relapsed/Refractory BCP-ALL
- Blinatumomab (BiTE): improves DFS and OS in relapsed B-ALL and measurable residual disease (MRD+)
- Inotuzumab ozogamicin (anti-CD22 antibody-drug conjugate): ↑ CR rate and PFS vs chemo (risk: sinusoidal obstruction syndrome)
- CAR-T cells (anti-CD19 or anti-CD22): very high CR rates in refractory/2nd+ relapse; toxicities include cytokine release syndrome and neurotoxicity
- Hematopoietic stem cell transplant (HSCT): curative in 50–60% when done in first remission; 20–40% in relapse
— Goldman-Cecil Medicine, pp. 1924–1925
Prognosis
| Population | 5-Year Survival |
|---|---|
| Children | ~90% |
| Adolescents/young adults (≤40 yr) | 65–75% |
| Adults >60 years | <20% |
Favorable prognostic factors: younger age, low WBC at diagnosis, favorable cytogenetics (ETV6::RUNX1, hyperdiploidy), achievement of MRD-negative remission.
Poor prognostic factors: Ph+ (BCR::ABL1), KMT2A rearrangement (infants), hypodiploidy, BCR-ABL1–like ALL, older age.
— Goldman-Cecil Medicine, p. 1925; Quick Compendium, p. 256
This is a shared conversation. Sign in to Orris to start your own chat.